Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect

2003289 citationsJournal Articlebronze Open Access

Authors

Noriko Satoh · Kyoto Medical Center

Yoshihiro Ogawa · Tokyo Medical and Dental University

Takeshi Usui · Kyoto Medical Center

Tetsuya Tagami · Kyoto Medical Center

Shigeo Kono · Kyoto Medical Center

Hiroko Uesugi · Saiseikai Ibaraki Hospital

Hiroyuki Sugiyama ·

Abstract

This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.

Topics & Keywords

Adipokines, Inflammation, and Metabolic Diseases Peroxisome Proliferator-Activated Receptors Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 26, Issue 9, pp. 2493-2499

DOI: 10.2337/diacare.26.9.2493

Field-Weighted Citation Impact: 25.09